Clinical Trial Update: Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating empagliflozin for heart failure with reduced ejection fraction in patients with end-stage renal disease on dialysis is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Heart Failure with Reduced Ejection Fraction, End Stage Renal Disease on Dialysis | Phase 4 | Status: RECRUITING